Adalimumab Improves Health-Related Quality of Life in Patients with Moderate to Severe Hidradenitis Suppurativa: Results from the First 12 Weeks of PIONEER II

The document reports on a multicenter study that evaluated the impact of adalimumab (ADA) on health-related quality of life (HRQoL) in patients with moderate to severe hidradenitis suppurativa (HS) over a 12-week period. The study was double-blind and placebo-controlled, with patients randomized to receive either ADA or a placebo. The study found that patients treated with ADA experienced significantly greater improvements in HRQoL compared to those receiving the placebo. This was measured using the EQ-5D index score, which improved by 0.1 for ADA patients versus no change for placebo patients (P < .001), and the visual analog scale (VAS), which improved by 9.2 for ADA patients versus 0.5 for placebo patients (P < .001). Additionally, ADA patients showed a significantly larger improvement in the Dermatology Life Quality Index (DLQI), with a change of 5.1 compared to 2.3 for placebo (P < .001). The study was funded and supported by AbbVie, which also participated in data interpretation and review.